BackCaliPharms Overview

CaliPharms Long Term Debt

Track CaliPharms's long-term debt ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$0.00

Peer average

Loading

CaliPharms Long Term Debt History

Loading

CaliPharms vs. peers: Long Term Debt Comparison

Loading

CaliPharms Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

CaliPharms (KGET) FAQ

As of the most recent data (September 2014), KGET shows a long-term debt of $0. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, KGET's long-term debt is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether CaliPharms is outperforming or lagging.

Tracking KGET's long-term debt over time shows whether CaliPharms is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has CaliPharms's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $0) with ownership activity and broader fundamentals.

CaliPharms's long-term debt is $0; compare it with other Industrials names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.